Pharmaceutical - Pharmaceutical, North America, BioMarin Pharmaceutical

FDA approves Vimizim to treat rare congenital enzyme disorder

FDA approves Vimizim to treat rare congenital enzyme disorder

17-02-2014

The US Food and Drug Administration on Friday (February 14) approved BioMarin Pharmaceutical’s Vimizim…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

FDA committee recommends approval for BioMarin's Vimizim

FDA committee recommends approval for BioMarin's Vimizim

20-11-2013

A US Food and Drug Administration panel has voted in favor of approval of Vimizim for the treatment of…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

BioMarin's Vimizim BLA accepted by FDA and MAA validated by EMA

30-05-2013

US drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) says that the Food and Drug Administration has accepted…

BioMarin PharmaceuticalEuropeNorth AmericaPharmaceuticalRare diseasesRegulationVimizim

Catalyst Pharma partners with BioMarin for Firdapse in North America

31-10-2012

Catalyst Pharmaceutical Partners (Nasdaq: CPRX) and fellow USA-based BioMarin Pharmaceutical (Nasdaq:…

BioMarin PharmaceuticalCatalyst PharmaceuticalFirdapseLicensingNorth AmericaPharmaceuticalRare diseases

Parexel

Parexel

Back to top